Merck & Co., Inc. (NYSE:MRK) Shares Sold by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC trimmed its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 2.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 87,932 shares of the company’s stock after selling 1,895 shares during the quarter. Merck & Co., Inc. comprises approximately 1.5% of KMG Fiduciary Partners LLC’s portfolio, making the stock its 12th biggest position. KMG Fiduciary Partners LLC’s holdings in Merck & Co., Inc. were worth $8,017,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Landmark Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $25,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $25,000. Front Row Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 89.4% in the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after acquiring an additional 160 shares during the period. Okabena Investment Services Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Finally, Western Pacific Wealth Management LP acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $29,000. 73.33% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 3.5 %

Shares of MRK stock opened at $87.51 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The stock has a market cap of $221.69 billion, a P/E ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33. Merck & Co., Inc. has a fifty-two week low of $71.50 and a fifty-two week high of $95.72. The business has a fifty day simple moving average of $88.83 and a 200-day simple moving average of $87.81.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.20. The business had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The business’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 earnings per share. On average, analysts forecast that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is currently 42.27%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MRK. Daiwa Capital Markets raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their price objective for the company from $89.00 to $102.00 in a report on Wednesday, July 6th. Berenberg Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their price target for the stock from $95.00 to $100.00 in a research note on Wednesday, September 14th. Mizuho started coverage on Merck & Co., Inc. in a research note on Friday, June 24th. They set a “buy” rating and a $100.00 price target for the company. Cowen upped their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Finally, Erste Group Bank upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $98.28.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.